title: Intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder: pilot study.
abstract: We conducted the first-regenerative medicine cellular therapy for underactive bladder (UAB) in an FDA-approved, compassionate-use IND trial to evaluate treatment safety and potential clinical efficacy of autologous muscle-derived stem cells (AMDC) on a patient with UAB. No study-related adverse events or side effects were reported. In the 1-year follow-up period, the subject denied any gross hematuria, urgency, frequency or infection. A reduction in maximum cystometric capacity from 844 to 663 mL was observed, and the patient was able to void small amounts but continues to require self-catheterization 1 year after AMDC injection. Intradetrusor injection of AMDC is safe, minimally invasive and a promising treatment option for the UAB.
authors: Department of Urology, Aikens Center of Neurourology Research, William Beaumont Hospital, Royal Oak, MI, USA.
authors: Peter E
authors: PE
authors: Levanovich
authors: Ananias
authors: A
authors: Diokno
authors: Deborah L
authors: DL
authors: Hasenau
authors: Michelle
authors: M
authors: Lajiness
authors: Ryan
authors: R
authors: Pruchnic
authors: Michael B
authors: MB
authors: Chancellor
mesh_terms: D000368:Aged; D002908:Chronic Disease; D057176:Compassionate Use Trials; D006801:Humans; D007273:Injections, Intramuscular / Q000379:methods; D057928:Intermittent Urethral Catheterization; D008297:Male; D032448:Myoblasts, Skeletal / Q000637:transplantation*; D010865:Pilot Projects; D001743:Urinary Bladder; D001745:Urinary Bladder Diseases / Q000150:complications / Q000628:therapy*; D016055:Urinary Retention / Q000209:etiology